The Rationale for and Clinical Pharmacology of Prasugrel 5 mg

Joseph A. Jakubowski, David Erlinge, Dimitrios Alexopoulos, David S. Small, Kenneth J. Winters, Paul A. Gurbel, Dominick J. Angiolillo

Research output: Contribution to journalReview articlepeer-review

Abstract

Prasugrel is a third-generation thienopyridine platelet P2Y12 adenosine diphosphate (ADP) receptor antagonist administered with aspirin for the treatment of patients with acute coronary syndrome (ACS) with planned percutaneous coronary intervention. Prasugrel is administered periprocedurally at an oral loading dose of 60 mg followed by daily maintenance doses (MDs) of 10 mg for most patients and 5 mg for patients weighing <60 kg or aged ≥75 years. Data from a prasugrel phase III study, TRITON-TIMI 38, suggested that a lower MD might be more suitable for patients weighing <60 kg or aged ≥75 years; subsequent pharmacokinetic and pharmacodynamic studies have indicated that prasugrel 5 mg reduced platelet reactivity in these populations to an extent similar to that of prasugrel 10 mg in heavier or younger patients. Clinical experience with prasugrel 5 mg is limited, and additional studies are needed to verify the clinical efficacy and safety of this dose in these challenging populations.

Original languageEnglish (US)
Pages (from-to)109-121
Number of pages13
JournalAmerican Journal of Cardiovascular Drugs
Volume17
Issue number2
DOIs
StatePublished - Apr 1 2017

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The Rationale for and Clinical Pharmacology of Prasugrel 5 mg'. Together they form a unique fingerprint.

Cite this